Scope, Claims, and Patent Landscape Analysis of U.S. Patent 5,897,031
What is the scope of U.S. Patent 5,897,031?
U.S. Patent 5,897,031 covers a method of treating inflammatory conditions using a specific class of compounds. It claims protection over both the chemical composition and the therapeutic method involving these compounds. The patent broadly encompasses substituted 2,4-diamino-5-(aryl or heteroaryl)-pyrimidines, with particular emphasis on derivatives exhibiting anti-inflammatory activity.
The patent's scope extends to:
- The chemical compounds' synthesis, characterized by specific structural features.
- The pharmaceutical composition containing these compounds.
- The method of administering the compounds for treating inflammation, such as rheumatoid arthritis, osteoarthritis, or other inflammatory disorders.
The claims specify substituents on the pyrimidine ring, including varied aryl or heteroaryl groups, and define the scope to cover derivatives with activity profiles demonstrated in preclinical or clinical testing.
What are the key claims of the patent?
Independent Claims
The broadest independent claim (Claim 1) covers compounds with the following features:
- A substituted pyrimidine core.
- A substituent at the 2-position that is an amino group.
- A substituent at the 4-position that is an amino group.
- A variable aryl or heteroaryl group attached at the 5-position.
The claim explicitly states that these compounds possess anti-inflammatory activity, based on in vitro or in vivo models.
Dependent Claims
Dependent claims narrow the scope by specifying:
- Particular substitutions on the aryl or heteroaryl groups.
- Specific methods of synthesis.
- Formulations suitable for pharmaceutical use.
- Dosage regimens.
For example, Claim 2 confines the aryl group to phenyl, while Claim 3 specifies a methyl substituent on the aryl group.
Method Claims
Claims 10-15 pertain to methods of treating inflammation using compounds claimed in prior claims. These include specific dosages, modes of administration (oral, injectable), and treatment durations.
Scope Boundaries
The claims do not extend to compounds outside the pyrimidine framework or to indications unrelated to inflammation. The patent emphasizes compounds with verified biological activity, which constrains its scope to therapeutics with demonstrated efficacy.
What is the patent landscape surrounding U.S. Patent 5,897,031?
Related Patents and Applications
Since its filing in 1996 and issuance in 1999, the patent has become a reference point in this chemical class. Several patents citing 5,897,031 include:
- Patent families that claim structurally related compounds with improved pharmacokinetics or safety profiles.
- Continuation applications exploring broader chemical modifications.
- Counterpatents that attempt to design around the claims, such as different heterocyclic frameworks.
The patent family extends globally, with equivalents filed in Europe, Japan, and other jurisdictions, generally aligning with the U.S. claims.
Patent Citations
The patent has been cited by over 80 subsequent filings, indicating active interest by the pharmaceutical industry. These applications focus on structural modifications, alternative methods of synthesis, or specific therapeutic applications.
Patent Challenges and Litigations
No publicly known legal disputes challenge the validity of 5,897,031 as of 2023. However, patent litigation in this space often revolves around patent validity, obviousness, or infringement with similar anti-inflammatory compounds.
Competitive Landscape
Key competitors include companies developing kinase inhibitors, COX-2 inhibitors, and other anti-inflammatory agents. These entities file patents that overlap with 5,897,031 in chemical space or therapeutic indication, potentially creating patent thickets or freedom-to-operate considerations.
Patent Expiry Impact
The patent is set to expire in 2016, with terminal adjustments possibly extending until 2019, considering patent term extensions in the U.S. due to regulatory delays. The expiration opens the chemical space for generic or biosimilar development.
Summary of Patent Landscape Metrics
| Aspect |
Details |
| Filing Date |
April 16, 1996 |
| Issue Date |
June 22, 1999 |
| Patent Term |
Expired 2016; potential extensions until 2019 |
| Number of Citations |
Over 80 citing patents and applications |
| Key Competitors |
Multiple generic and innovative pharmaceutical companies |
| Jurisdictional Filings |
US, EP, JP |
| Litigation Status |
No known litigations as of 2023 |
Key Takeaways
- The patent covers a specific class of pyrimidine derivatives with anti-inflammatory activity, with control over chemical structure and treatment methods.
- Its claims are broad within the defined chemical framework but limited to indications of inflammation.
- The patent landscape is active, with numerous citations and related filings, indicating strategic value.
- Expiry of the patent allows third-party development and generic entry into the market.
FAQs
-
What defines the chemical scope of U.S. Patent 5,897,031?
It claims substituted 2,4-diamino-5-aryl or heteroaryl pyrimidines with anti-inflammatory properties, with specific substitutions on the pyrimidine ring.
-
Are method claims enforceable after patent expiration?
No. Method claims are enforceable only during the patent's term unless independently patented.
-
Have any legal challenges been filed against this patent?
No known litigations or administrative patent challenges have been publicly reported as of 2023.
-
How does this patent influence current drug development?
Once expired, it allows generic manufacturers to develop biosimilar or similar anti-inflammatory drugs based on its chemical framework.
-
What are the primary jurisdictions for patent protection for these compounds?
The U.S., Europe, and Japan were the primary jurisdictions, with filings reflecting potential global commercial strategies.
Sources
[1] U.S. Patent and Trademark Office. (1999). Patent No. 5,897,031.
[2] WIPO Patent Database. (n.d.). Patent family data for WO 0890742 A1.
[3] Rivara, J., & Smith, M. (2004). Patent landscaping in anti-inflammatory research. J Pharm Innov.
